Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 5462

Next Previous
Drug Profile

AZD 5462

Alternative Names: AZD-5462

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Heart failure therapies; Small molecules
  • Mechanism of Action RXFP1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure

Most Recent Events

  • 19 May 2025 AstraZeneca plans a phase I pharmacokinetic trial in Heart failure (In volunteers) in United Kingdom (PO. Tablet) in May 2025 (NCT06989983)
  • 23 Dec 2024 AstraZeneca completes a phase I pharmacokinetics trials in Bulgaria (PO) (NCT06661733) (EUCT-2024-514359-14-00)
  • 18 Nov 2024 AstraZeneca initiates enrolment in a phase I pharmacokinetics trials in Bulgaria (PO) (NCT06661733) (EUCT-2024-514359-14-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top